{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:35:49Z","timestamp":1785458149990,"version":"3.56.0"},"reference-count":127,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/50006\/2020"],"award-info":[{"award-number":["UIDB\/50006\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/50011\/2020"],"award-info":[{"award-number":["UIDB\/50011\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDP\/50011\/2020"],"award-info":[{"award-number":["UIDP\/50011\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PD\/BD\/135104\/2017"],"award-info":[{"award-number":["PD\/BD\/135104\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>The present review describes the various roles of cyclodextrins (CDs) in vaccines against viruses and in antiviral therapeutics. The first section describes the most commonly studied application of cyclodextrins\u2014solubilisation and stabilisation of antiviral drugs; some examples also refer to their beneficial taste-masking activity. The second part of the review describes the role of cyclodextrins in antiviral vaccine development and stabilisation, where they are employed as adjuvants and cryopreserving agents. In addition, cyclodextrin-based polymers as delivery systems for mRNA are currently under development. Lastly, the use of cyclodextrins as pharmaceutical active ingredients for the treatment of viral infections is explored. This new field of application is still taking its first steps. Nevertheless, promising results from the use of cyclodextrins as agents to treat other pathologies are encouraging. We present potential applications of the results reported in the literature and highlight the products that are already available on the market.<\/jats:p>","DOI":"10.3390\/pharmaceutics13030409","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T11:18:38Z","timestamp":1616152718000},"page":"409","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Cyclodextrins in Antiviral Therapeutics and Vaccines"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4460-970X","authenticated-orcid":false,"given":"Susana","family":"Braga","sequence":"first","affiliation":[{"name":"LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7220-661X","authenticated-orcid":false,"given":"J\u00e9ssica","family":"Barbosa","sequence":"additional","affiliation":[{"name":"LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal"},{"name":"CICECO\u2014Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4560-6172","authenticated-orcid":false,"given":"N\u00e1dia","family":"Santos","sequence":"additional","affiliation":[{"name":"LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5796-7605","authenticated-orcid":false,"given":"Firas","family":"El-Saleh","sequence":"additional","affiliation":[{"name":"Ashland Specialty Ingredients, Paul-Thomas Strasse, 56, D-40599 D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2051-5645","authenticated-orcid":false,"given":"Filipe","family":"Paz","sequence":"additional","affiliation":[{"name":"CICECO\u2014Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/jmv.25683","article-title":"Global health concerns stirred by emerging viral infections","volume":"92","author":"Luo","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: A systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"Roth","year":"2018","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/423240a","article-title":"Koch\u2019s postulates fulfilled for SARS virus","volume":"423","author":"Fouchier","year":"2003","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1126\/science.1189132","article-title":"Reassortment of pandemic H1N1\/2009 influenza A virus in swine","volume":"328","author":"Vijaykrishna","year":"2010","journal-title":"Science"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(15)60454-8","article-title":"Middle East respiratory syndrome","volume":"386","author":"Zumla","year":"2015","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev-pathol-052016-100506","article-title":"The pathogenesis of Ebola virus disease","volume":"12","author":"Baseler","year":"2017","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Connors, M.D., Graham, B.S., Lane, H.C., and Fauci, A.S. (2021). SARS-CoV-2 Vaccines: Much accomplished, much to learn. Ann. Intern. Med., Epub ahead of print.","DOI":"10.7326\/M21-0111"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e00598","DOI":"10.1128\/mBio.00598-13","article-title":"A strategy to estimate unknown viral diversity in mammals","volume":"4","author":"Anthony","year":"2013","journal-title":"mBio"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.virusres.2019.02.011","article-title":"Drug repurposing for new, efficient, broad spectrum antivirals","volume":"264","author":"Risco","year":"2019","journal-title":"Virus Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijid.2020.02.018","article-title":"Discovery and development of safe-in-man broad-spectrum antiviral agents","volume":"93","author":"Andersen","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1038\/s41467-020-16048-4","article-title":"Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig","volume":"11","author":"Lei","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"ref_13","first-page":"1021","article-title":"Cyclodextrin affects distinct tissue drug disposition as a novel drug delivery vehicle","volume":"2","author":"Li","year":"2019","journal-title":"Ann. Med. Med. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jconrel.2007.07.018","article-title":"The utility of cyclodextrins for enhancing oral bioavailability","volume":"123","author":"Carrier","year":"2007","journal-title":"J. Control. Release"},{"key":"ref_15","first-page":"1","article-title":"Approved pharmaceutical products containing cyclodextrins","volume":"26","author":"Fenyvesi","year":"2013","journal-title":"Cyclodext. News"},{"key":"ref_16","unstructured":"European Medicines Agency (2014). Background Review for Cyclodextrins Used as Excipients, EMA. Available online: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2014\/12\/WC500177936.pdf."},{"key":"ref_17","first-page":"185","article-title":"Applications of cyclodextrins in cosmetic products: A review","volume":"53","author":"Buschmann","year":"2002","journal-title":"J. Cosmet. Sci."},{"key":"ref_18","unstructured":"Grumezescu, A. (2018). Getting under the skin: Cyclodextrin inclusion for the controlled delivery of active substances to the dermis. Design of Nanostructures for Versatile Therapeutic Applications, Elsevier. [1st ed.]. Chapter 10."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.3109\/10717544.2016.1170247","article-title":"Montelukast medicines of today and tomorrow: From molecular pharmaceutics to technological formulations","volume":"23","author":"Barbosa","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0032-9592(03)00258-9","article-title":"Cyclodextrins and their uses: A review","volume":"39","year":"2004","journal-title":"Process. Biochem."},{"key":"ref_21","first-page":"95","article-title":"Cyclodextrins\u2014A Review on pharmaceutical application for drug delivery","volume":"2","author":"Agrawal","year":"2012","journal-title":"Int. J. Pharm. Front. Res."},{"key":"ref_22","unstructured":"Kroes, R., Verger, P., and Larsen, J.C. (2006). Safety Evaluation of Certain Food Additives (\u03b1-Cyclodextrin-Addendum), WHO."},{"key":"ref_23","unstructured":"Pollit, F.D. (1996). Safety Evaluation of Certain Food Additives (\u03b2-Cyclodextrin), WHO."},{"key":"ref_24","unstructured":"Abbott, P.J. (2000). JEFCA 55th Meeting: Safety Evaluation of Certain Food Additives and Contaminants (\u03b3-Cyclodextrin), WHO."},{"key":"ref_25","unstructured":"(2004). Agency Response Letter Gras Notice GRN No. 155."},{"key":"ref_26","unstructured":"(2001). Agency Response Letter Gras Notice GRN No. 74."},{"key":"ref_27","unstructured":"(2000). Agency Response Letter Gras Notice GRN No. 46."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1248\/bpb1978.5.741","article-title":"Cyclodextrin-induced hemolysis and shape changes of human erythrocytes in vitro","volume":"5","author":"Irie","year":"1982","journal-title":"J. Pharm. Dyn."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1432-1033.1989.tb15171.x","article-title":"Differential effects of \u03b1-, \u03b2- and \u03b3-cyclodextrins on human erythrocytes","volume":"186","author":"Ohtani","year":"1989","journal-title":"Eur. J. Biochem."},{"key":"ref_30","first-page":"1","article-title":"The cyclodextrins: A review","volume":"10","author":"Nitalikar","year":"2012","journal-title":"J. Curr. Pharm. Res."},{"key":"ref_31","unstructured":"Szycher, M. (1991). Pharmaceutical uses of Cyclodextrin Derivatives. High Performance Biomaterials, A Comprehensive Guide to Medical and Pharmaceutical Applications, Technomic. [1st ed.]."},{"key":"ref_32","unstructured":"(2021, February 24). Excipients in Vaccines per 0.5 mL Dose. Available online: https:\/\/www.vaccinesafety.edu\/components-Excipients.htm."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Szente, L., Singhal, A., Domokos, A., and Song, B. (2018). Cyclodextrins: Assessing the impact of cavity size, occupancy, and substitutions on cytotoxicity and cholesterol homeostasis. Molecules, 23.","DOI":"10.3390\/molecules23051228"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ejps.2010.04.014","article-title":"Evaluation of the cytotoxicity of \u03b2-cyclodextrin derivatives: Evidence for the role of cholesterol extraction","volume":"40","author":"Kiss","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_35","unstructured":"(2019, September 17). Captisol. Available online: https:\/\/www.captisol.com\/technology\/history."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.clindermatol.2003.08.012","article-title":"Changing paradigms in dermatology: Antivirals in dermatology","volume":"21","author":"Lin","year":"2003","journal-title":"Clin. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1128\/AAC.46.7.2238-2243.2002","article-title":"Acyclovir cream for treatment of herpes simplex labialis: Results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials","volume":"46","author":"Spruance","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1002\/jps.21392","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: Aciclovir","volume":"97","author":"Arnal","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"ref_39","first-page":"101","article-title":"Formulation development and evaluation of acyclovir orally disintegrating tablets","volume":"2","author":"Karpe","year":"2012","journal-title":"J. Appl. Pharm. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1590\/S0100-40422000000600007","article-title":"Inclusion complex of the antiviral drug acyclovir with cyclodextrin in aqueous solution and in solid phase","volume":"23","author":"Rossel","year":"2000","journal-title":"Qu\u00edm. Nova"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/10837450903262017","article-title":"Controlled release polymeric ocular delivery of acyclovir","volume":"15","author":"Deshpande","year":"2010","journal-title":"Pharm. Dev. Technol."},{"key":"ref_42","first-page":"341","article-title":"Enhancement of solubility of acyclovir by solid dispersion and inclusion complexation methods","volume":"2","author":"Tomar","year":"2010","journal-title":"Pharm. Lett."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1002\/jps.10245","article-title":"Preliminary pharmacokinetic study of different preparations of acyclovir with \u03b2-cyclodextrin","volume":"91","author":"Luengo","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3109\/10717544.2013.853213","article-title":"Enhanced oral bioavailability of acyclovir by inclusion complex using hydroxypropyl-\u03b2-cyclodextrin","volume":"21","author":"Nair","year":"2014","journal-title":"Drug Deliv."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jconrel.2007.11.004","article-title":"Preparation and in vitro evaluation of the antiviral activity of the Acyclovir complex of a \u03b2-cyclodextrin\/poly(amidoamine) copolymer","volume":"126","author":"Bencini","year":"2008","journal-title":"J. Control. Release"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10847-018-0829-6","article-title":"Exploring the entrapment of antiviral agents in hyaluronic acid-cyclodextrin conjugates","volume":"93","author":"Piperno","year":"2019","journal-title":"J. Incl. Phenom. Macrocycl."},{"key":"ref_47","unstructured":"(2020, November 18). Cytovene. Available online: https:\/\/www.rxlist.com\/cytovene-drug.htm."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1023\/A:1016462801968","article-title":"Selection of a derivative of the antiviral agent 9-[1,3(dihydroxy)-2-(propoxy)-methyl]guanine (DHPG) with improved oral absorption","volume":"4","author":"Benjamin","year":"1987","journal-title":"Pharm. Res."},{"key":"ref_49","unstructured":"(2020, November 19). Ganciclovir Sodium. Available online: https:\/\/go.drugbank.com\/salts\/DBSALT000309."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1128\/AAC.06423-11","article-title":"Pharmacodynamic model of ganciclovir antiviral effect and toxicity for lymphoblastoid cells suggests a new dosing regimen to treat cytomegalovirus infection","volume":"56","author":"Rouvet","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0968-0896(00)00247-9","article-title":"Effect of the complexation with cyclodextrins on the in vitro antiviral activity of ganciclovir against human cytomegalovirus","volume":"9","author":"Nicolazzi","year":"2001","journal-title":"Bioorg. Med. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0166-3542(01)00218-2","article-title":"In vitro antiviral efficacy of the ganciclovir complexed with \u03b2-cyclodextrin on human cytomegalovirus clinical strains","volume":"54","author":"Nicolazzi","year":"2002","journal-title":"Antivir. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1208\/pt040345","article-title":"Effect of hydroxypropyl beta cyclodextrin complexation on aqueous solubility, stability, and corneal permeation of acyl ester prodrugs of ganciclovir","volume":"4","author":"Tirucherai","year":"2003","journal-title":"AAPS Pharm. Sci. Tech."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Braga, S.S., Lysenko, K., El-Saleh, F., and Almeida Paz, F.A. (2021). Cyclodextrin-efavirenz complexes investigated by solid state and solubility studies. Proceedings, 78.","DOI":"10.3390\/IECP2020-08690"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/jps.23380","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: Efavirenz","volume":"102","author":"Cristofoletti","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1208\/s12249-008-9180-3","article-title":"Physicochemical characterization of efavirenz-cyclodextrin inclusion complexes","volume":"10","author":"Sathigari","year":"2009","journal-title":"AAPS Pharm. Sci. Tech."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/masy.201050108","article-title":"Synthesis of cyclodextrin and sugar-based oligomers for the efavirenz drug delivery","volume":"287","author":"Shown","year":"2010","journal-title":"Macromol. Symp."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Braga, S.S., El-Saleh, F., Lysenko, K., and Paz, F.A.A. (2021). Inclusion compound of efavirenz and \u03b3-cyclodextrin: Solid state studies and effect on solubility. Molecules, 26.","DOI":"10.3390\/molecules26030519"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.carbpol.2015.04.050","article-title":"Multicomponent systems with cyclodextrins and hydrophilic polymers for the delivery of efavirenz","volume":"130","author":"Vieira","year":"2015","journal-title":"Carbohydr. Polym."},{"key":"ref_60","first-page":"130","article-title":"Formulation development of efavirenz tablets employing \u03b2 cyclodextrin-PVP K30-SLS: A factorial study","volume":"1","author":"Chowdary","year":"2011","journal-title":"J. Appl. Pharm. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1208\/s12249-018-1064-6","article-title":"Investigation of cyclodextrin-based nanosponges for solubility and bioavailability enhancement of rilpivirine","volume":"19","author":"Rao","year":"2018","journal-title":"AAPS Pharm. Sci. Tech."},{"key":"ref_62","unstructured":"(2021, February 11). Australian Public Assessment Report for Rilpivirine, Available online: https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-rilpivirine-120327.pdf."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"31","DOI":"10.25004\/IJPSDR.2018.100106","article-title":"Enhancement of solubility of rilpivirine by inclusion complexation with cyclodextrins","volume":"10","author":"Srivani","year":"2018","journal-title":"Int. J. Pharm. Sci. Drug Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1080\/03639045.2017.1371732","article-title":"Enhancement of oral bioavailability of anti-HIV drug rilpivirine HCl through nanosponge formulation","volume":"43","author":"Zainuddin","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/jac\/dkh487","article-title":"The intracellular pharmacology of antiretroviral protease inhibitors","volume":"54","author":"Ford","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1021\/bm700827h","article-title":"Pharmacokinetics of saquinavir after intravenous and oral dosing of saquinavir: Hydroxybutenyl-\u03b2-cyclodextrin formulations","volume":"9","author":"Buchanan","year":"2008","journal-title":"Biomacromolecules"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ejps.2010.07.013","article-title":"Enhanced oral absorption of saquinavir with methyl-beta-cyclodextrin\u2014Preparation and in vitro and in vivo evaluation","volume":"41","author":"Pathak","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ejpb.2011.08.005","article-title":"Preparation and solid-state characterization of ball milled saquinavir mesylate for solubility enhancement","volume":"80","author":"Branham","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0378-5173(01)00622-6","article-title":"Combined hydroxypropyl-\u03b2-cyclodextrin and poly(alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir","volume":"218","author":"Boudad","year":"2001","journal-title":"Int. J. Pharm."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10847-012-0269-7","article-title":"Solubility and dissolution enhancement of saquinavir mesylate by inclusion complexation technique","volume":"76","author":"Mahajan","year":"2013","journal-title":"J. Incl. Phenom. Macrocycl. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A Trial of lopinavir\u2013ritonavir in adults hospitalized with severe covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.therap.2020.05.002","article-title":"French Network of Pharmacovigilance Centers. \u201cOff-label\u201d use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers","volume":"75","author":"Romani","year":"2020","journal-title":"Therapies"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10847-011-0022-7","article-title":"Complexation approach for fixed dose tablet formulation of lopinavir and ritonavir: An anomalous relationship between stability constant, dissolution rate and saturation solubility","volume":"73","author":"Goyal","year":"2012","journal-title":"J. Incl. Phenom. Macrocycl. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1002\/jps.24492","article-title":"Enhanced boosting of oral absorption of lopinavir through electrospray coencapsulation with ritonavir","volume":"104","author":"Sakuma","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1086\/382531","article-title":"Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains Lopinavir-Ritonavir","volume":"38","author":"Domingo","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"115287","DOI":"10.1016\/j.carbpol.2019.115287","article-title":"Cyclodextrin solubilization and complexation of antiretroviral drug lopinavir: In silico prediction; Effects of derivatization, molar ratio and preparation method","volume":"227","author":"Adeoye","year":"2020","journal-title":"Carbohydr. Polym."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0378-5173(03)00164-9","article-title":"Pharmacokinetics and delivery of the anti-influenza prodrug oseltamivir to the small intestine and colon using site-specific delivery capsules","volume":"257","author":"Oo","year":"2003","journal-title":"Int. J. Pharm."},{"key":"ref_78","unstructured":"(2021, February 08). Molecule of the Week: Oseltamivir Phosphate. Available online: https:\/\/www.acs.org\/content\/acs\/en\/molecule-of-the-week\/archive\/o\/oseltamivir-phosphate.html."},{"key":"ref_79","first-page":"583","article-title":"Novel inclusion complexs of oseltamivir phosphate-with \u03b2 cyclodextrin: Physico-chemical characterization","volume":"2","author":"Sevukarajan","year":"2010","journal-title":"J. Pharm. Sci. Res."},{"key":"ref_80","unstructured":"Li, C. (2011). Improved Oseltamivir Phosphate Medicinal Composition. (CN102068425A), Chinese Patent."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19\u2014Final Report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_83","unstructured":"European Medicines Agency (2021, February 09). Summary on Compassionate Use\u2014Remdesivir Gilead. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/other\/summary-compassionate-use-remdesivir-gilead_en.pdf."},{"key":"ref_84","unstructured":"Food and Drug Administration (2021, February 09). Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment."},{"key":"ref_85","unstructured":"Food and Drug Administration (2021, February 09). Remdesivir Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/214787Orig1s000lbl.pdf."},{"key":"ref_86","first-page":"42","article-title":"Application of Captisol\u00ae Technology to Enable the Formulation of Remdesivir in Treating COVID-19","volume":"20","author":"Pipkin","year":"2020","journal-title":"Drug Dev. Deliv."},{"key":"ref_87","unstructured":"(2021, March 11). Janssen COVID-19 Vaccine, Available online: https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/janssen-covid-19-vaccine."},{"key":"ref_88","unstructured":"(2021, March 11). EMA Recommends COVID-19 Vaccine Janssen for Authorisation in the EU. Available online: https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-covid-19-vaccine-janssen-authorisation-eu."},{"key":"ref_89","unstructured":"(2021, February 24). Label: JANSSEN COVID-19 VACCINE\u2014ad26.cov2.s Injection, Suspension, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=14a822ff-f353-49f9-a7f2-21424b201e3b."},{"key":"ref_90","unstructured":"Adriaansen, J., and Hesselink, R.W. (2017). Methods for Preventing Surface-Induced Degradation of Viruses Using Cyclodextrins. (CA3001050A1), Canadian Patent."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Braga, S.S. (2019). Cyclodextrins: Emerging medicines of the new millennium. Biomolecules, 9.","DOI":"10.3390\/biom9120801"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0264-410X(98)00195-9","article-title":"Sulfolipo-cyclodextrin in squalane-in-water as a novel and safe vaccine adjuvant","volume":"17","author":"Hilgers","year":"1999","journal-title":"Vaccine"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0264-410X(00)00104-3","article-title":"Adjuvant effects of sulfolipo-cyclodextrin in a squalane-in-water and water-in-mineral oil emulsions for BHV-1 vaccines in cattle","volume":"19","author":"Romera","year":"2001","journal-title":"Vaccine"},{"key":"ref_94","unstructured":"European Medicines Agency (2021, February 10). Suvaxyn PCV Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/veterinary\/EPAR\/suvaxyn-pcv#product-information-section."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.4049\/jimmunol.1402027","article-title":"Hydroxypropyl-\u03b2-cyclodextrin spikes local inflammation that induces Th2 cell and T follicular helper cell responses to the coadministered antigen","volume":"194","author":"Onishi","year":"2015","journal-title":"J. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3389\/fimmu.2016.00435","article-title":"Induction of dendritic cell maturation and activation by a potential adjuvant, 2-hydroxypropyl-\u03b2-cyclodextrin","volume":"7","author":"Kim","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_97","unstructured":"(2021, February 09). A Phase 1 Study of Hydroxypropyl-beta-cyclodextrin(HP-beta-CyD)-Adjuvanted Influenza Split Vaccine. Available online: https:\/\/rctportal.niph.go.jp\/en\/detail?trial_id=UMIN000028530."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1016\/j.vaccine.2016.04.001","article-title":"Intranasal hydroxypropyl-\u03b2-cyclodextrin-adjuvanted influenza vaccine protects against sub-heterologous virus infection","volume":"34","author":"Kusakabe","year":"2016","journal-title":"Vaccine"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4155\/tde-2016-0006","article-title":"mRNA vaccine delivery using lipid nanoparticles","volume":"7","author":"Reichmuth","year":"2016","journal-title":"Ther. Deliv."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Kaiser, J. (2020). Temperature concerns could slow the rollout of new coronavirus vaccines. Science, Available online: https:\/\/www.sciencemag.org\/news\/2020\/11\/temperature-concerns-could-slow-rollout-new-coronavirus-vaccines.","DOI":"10.1126\/science.abf7422"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s13346-020-00724-5","article-title":"Cyclodextrins in drug delivery: Applications in gene and combination therapy","volume":"10","author":"Haley","year":"2020","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s13346-020-00725-4","article-title":"Optimization of an mRNA vaccine assisted with cyclodextrin-polyethyleneimine conjugates","volume":"10","author":"Tan","year":"2020","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature08956","article-title":"Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles","volume":"464","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"ref_104","unstructured":"(2019, September 08). Orphanet, Orphan Designation\u2014USA. Available online: https:\/\/www.orpha.net\/consor\/cgi-bin\/Drugs_Search.php?lng=EN&data_id=88421&search=Drugs_Search_Simple&data_type=Status&Typ=Sub."},{"key":"ref_105","unstructured":"(2019, September 08). Orphan Designation EU\/3\/13\/1124. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu3131124."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"333ra50","DOI":"10.1126\/scitranslmed.aad6100","article-title":"Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming","volume":"8","author":"Zimmer","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.4049\/jimmunol.1700302","article-title":"Cyclodextrin reduces cholesterol crystal\u2013induced inflammation by modulating complement activation","volume":"199","author":"Bakke","year":"2017","journal-title":"J. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10847-008-9510-9","article-title":"Study of the cholesterol extraction capacity of \u03b2-cyclodextrin and its derivatives, relationships with their effects on endothelial cell viability and on membrane models","volume":"63","author":"Castagne","year":"2009","journal-title":"J. Incl. Phenom. Macrocycl. Chem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"12169","DOI":"10.1128\/JVI.00835-07","article-title":"Lipid raft disruption by cholesterol depletion enhances influenza A virus budding from MDCK cells","volume":"81","author":"Barman","year":"2007","journal-title":"J. Virol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"12543","DOI":"10.1128\/JVI.77.23.12543-12551.2003","article-title":"Role for influenza virus envelope cholesterol in virus entry and infection","volume":"77","author":"Sun","year":"2003","journal-title":"J. Virol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Verma, D.K., Gupta, D., and Lal, S.K. (2018). Host lipid rafts play a major role in binding and endocytosis of Influenza A virus. Viruses, 10.","DOI":"10.3390\/v10110650"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.biomaterials.2015.11.034","article-title":"Pentacyclic triterpenes grafted on CD cores to interfere with influenza virus entry: A dramatic multivalent effect","volume":"78","author":"Xiao","year":"2016","journal-title":"Biomaterials"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejmech.2017.03.087","article-title":"Inhibition of influenza virus infection by multivalent pentacyclic triterpene-functionalized per-O-methylated cyclodextrin conjugates","volume":"134","author":"Tian","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.1128\/JVI.00117-08","article-title":"Cholesterol effectively blocks entry of flavivirus","volume":"82","author":"Lee","year":"2008","journal-title":"J. Virol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1099\/vir.0.015420-0","article-title":"Antibody-dependent enhancement of dengue virus infection in U937 cells requires cholesterol-rich membrane microdomains","volume":"91","author":"Mosso","year":"2010","journal-title":"J. Gen. Virol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.virusres.2013.03.005","article-title":"Requirement of cholesterol in the viral envelope for dengue virus infection","volume":"174","author":"Carro","year":"2013","journal-title":"Virus Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1099\/jgv.0.000881","article-title":"The dengue virus non-structural protein 1 (NS1) is secreted from infected mosquito cells via a non-classical caveolin-1-dependent pathway","volume":"98","author":"Medina","year":"2017","journal-title":"J. Gen. Virol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1007\/s10620-018-5401-0","article-title":"Hepatitis C virus entry into macrophages\/monocytes mainly depends on the phagocytosis of macrophages","volume":"64","author":"Liu","year":"2019","journal-title":"Digest. Dis. Sci."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1128\/JVI.00123-15","article-title":"Detergent-resistant membrane association of NS2 and E2 during hepatitis C virus replication","volume":"89","author":"Shanmugam","year":"2015","journal-title":"J. Virol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1016\/j.bmc.2012.07.029","article-title":"Conjugation of cyclodextrin with fullerene as a new class of HCV entry inhibitors","volume":"20","author":"Xiao","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1089\/088922203322280900","article-title":"Lipid rafts and HIV pathogenesis: Virion-associated cholesterol is required for fusion and infection of susceptible cells","volume":"19","author":"Liao","year":"2003","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"8237","DOI":"10.1128\/JVI.77.15.8237-8248.2003","article-title":"Cholesterol depletion of human immunodeficiency virus type 1 and simian immunodeficiency virus with \u03b2-cyclodextrin inactivates and permeabilizes the virions: Evidence for virion-associated lipid rafts","volume":"77","author":"Graham","year":"2003","journal-title":"J. Virol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1172\/JCI0213236","article-title":"Vaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent","volume":"109","author":"Khanna","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.1128\/JVI.02730-07","article-title":"Incomplete protection against simian immunodeficiency virus vaginal transmission in rhesus macaques by a topical antiviral agent revealed by repeat challenges","volume":"82","author":"Ambrose","year":"2008","journal-title":"J. Virol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000349991","article-title":"A Randomized, double-blind, placebo-controlled study to test the efficacy of topical 2-hydroxypropyl-beta-cyclodextrin in the prophylaxis of recurrent herpes labialis","volume":"226","author":"Senti","year":"2013","journal-title":"Dermatology"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"eaax9318","DOI":"10.1126\/sciadv.aax9318","article-title":"Modified cyclodextrins as broad-spectrum antivirals","volume":"6","author":"Jones","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_127","unstructured":"(2021, February 12). Pharmacology Review 20-966. Sporanox (Itraconazole) Injection, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/99\/20-966_SPORANOX%20INJECTION%2010MG%20PER%20ML_PHARMR.PDF."}],"updated-by":[{"DOI":"10.3390\/pharmaceutics14030499","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000}}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/3\/409\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T13:48:08Z","timestamp":1754228888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/3\/409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":127,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["pharmaceutics13030409"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics13030409","relation":{"correction":[{"id-type":"doi","id":"10.3390\/pharmaceutics14030499","asserted-by":"object"}]},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,19]]}}}